Valuation: Mendus AB

Market Cap 428M 45.24M 38.81M 36.24M 33.25M 62.53M 4.32B 63.56M 167M 2.17B 170M 166M 7.17B P/E 2026 *
-4.44x
P/E 2027 * -5.77x
Enterprise Value 106M 11.25M 9.65M 9.01M 8.27M 15.55M 1.08B 15.8M 41.64M 539M 42.24M 41.32M 1.78B EV / Sales 2026 *
17.8x
EV / Sales 2027 * 1.54x
Free-Float
34.33%
Yield 2026 *
-
Yield 2027 * -
1 day-1.47%
1 week+0.90%
Current month-3.31%
1 month+11.83%
3 months+17.51%
6 months+40.23%
Current year+19.82%
1 week 6.57
Extreme 6.57
7.5
1 month 6.27
Extreme 6.27
7.5
Current year 3.86
Extreme 3.86
7.5
1 year 3.86
Extreme 3.86
9.37
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 15/03/2021
Chief Executive Officer 76 12/12/2019
Director of Finance/CFO 60 27/02/2021
Director TitleAgeSince
Chairman 52 21/01/2021
Director/Board Member 64 31/12/2019
Director/Board Member 74 31/12/2012
Date Insider Type Main position Quantity % Market Cap.
28/02/22 Buy

Chief Technology Officer

10,000 0.0050%
24/02/22 Buy

Chief Financial Officer

10,000 0.0050%
24/02/22 Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-1.47%+0.90%-12.17%+0.30% 45.53M
+2.37%+2.30%+3.39%+22.74% 48.63B
-0.62%+4.58%+487.47%+624.71% 46.3B
+2.09%+4.96%+20.59%+95.21% 41.97B
+3.85%+3.13%+29.60%+16.50% 39.51B
-0.72%-3.91%+17.87%+47.98% 31.75B
+3.04%+1.89%+31.62%+143.62% 16.48B
+4.33%+1.63% - - 16.34B
+1.44%+1.52%+4.22%+31.00% 14B
+3.87%+1.98%+82.99%+45.80% 13.33B
Average +1.82%+1.45%+73.95%+114.21% 26.83B
Weighted average by Cap. +1.85%+0.96%+107.22%+157.18%

Financials

2026 *2027 *
Net sales 5.97M 631K 542K 506K 464K 872K 60.34M 887K 2.34M 30.26M 2.37M 2.32M 100M 150M 15.84M 13.58M 12.68M 11.64M 21.88M 1.51B 22.24M 58.61M 759M 59.46M 58.16M 2.51B
Net income -150M -15.89M -13.63M -12.73M -11.68M -21.96M -1.52B -22.32M -58.8M -762M -59.66M -58.36M -2.52B -66.57M -7.04M -6.04M -5.64M -5.18M -9.73M -673M -9.89M -26.07M -338M -26.45M -25.87M -1.12B
Net Debt -321M -33.99M -29.16M -27.23M -24.98M -46.98M -3.25B -47.75M -126M -1.63B -128M -125M -5.39B -197M -20.84M -17.88M -16.7M -15.32M -28.81M -1.99B -29.28M -77.14M -999M -78.26M -76.56M -3.3B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
19
Date Price Change Volume
19/08/26 SEK 6.710 -1.47% 66,587
18/08/26 SEK 6.810 -1.73% 16,127
17/08/26 SEK 6.930 +0.43% 11,257
14/08/26 SEK 6.900 +2.53% 26,075
13/08/26 SEK 6.730 +1.20% 21,041
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.710SEK
Average target price
33.00SEK
Spread / Average Target
+391.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock